The parent group Fresenius SE & Co. KG aA has increased its targets for infusion subsidiary Fresenius Kabi. The company developed well in all regions and product areas in the first half of 2012, and it is expected to continue this in the second half of the year.
In the USA, Fresenius Kabi expects continued high demand due to the continuing delays for I.V. drugs, in particular the anaesthetic Propofol, which according to reports are going to extend into the fourth quarter of the year.
Fresenius Kabi increased for the third time its forecast for the full year and now expects organic sales growth of nine percent and an operating margin (EBIT margin) of 20.5 percent.
Fresenius will invest the additional contribution from Kabi, in order to reduce future interest expense, and improve the maturity profile of its debt.
[ilink url=“http://www.fresenius.de/3926_4384.htm“] Link zur Quelle (Fresenius)[/ilink]